HM95573

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

NeoplasmsSolid Tumor

Phase 1

Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573

CompletedNCT02405065

Hanmi Pharmaceutical Company LimitedNeoplasms

Start: 2015-01-12End: 2018-05-16Updated: 2020-08-10

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers

CompletedNCT03118817

Hanmi Pharmaceutical Company LimitedSolid Tumor

Start: 2017-05-19End: 2020-02-04Updated: 2020-08-10

Related Papers

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.

2021-05-05106 citations

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Journal of Clinical Oncology2019-05-2046 citations

First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.

Journal of Clinical Oncology2016-05-204 citations